undamentalytics Newsletter
Sign in

Bio-Techne income statement

In fiscal 2026, Bio-Techne reported revenue of $1.22bn, down 0.4% on the year before, operating income of $252m (a 20.7% margin) and net income of $182m, or $1.16 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Revenue2692903153113584524995636437147399311,1061,1371,1591,2201,215
Cost of revenue55657979106145162188211241255298349367389429416
Gross profit214225236231251307337375432473483633756770770790799
Research and development2526282931414554556265718792979995
Selling, general and administrative3336424361119141200241264261325373378466589452
Operating income1561631660160147151121136147157237297299207102252
Interest expense———0022710221914111116910
Income before tax15616516216116115414711212611227614830133918698241
Income tax4753504850464336−0164793853182559
Net income110112112113111108104761269622914027228516873182
Diluted EPS$0.73$0.76$0.76$0.76$0.75$0.72$0.70$0.51$0.83$0.62$1.46$0.87$1.66$1.76$1.05$0.46$1.16
Diluted shares (average)149m149m148m148m148m149m149m150m152m156m158m162m164m162m161m160m157m
EBITDA16417217912179184193181201225240325398406318212349

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SHC vs TECHRGEN vs TECHNEO vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bio-Techne's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bio-Techne.